INCB 086550
Alternative Names: 86550-106; [14C]-INCB086550; INCB-086550; INCB-86550Latest Information Update: 28 Feb 2025
At a glance
- Originator Incyte Corporation
- Developer Incyte Biosciences Japan; Incyte Corporation
- Class Antineoplastics; Small molecules
- Mechanism of Action Programmed cell death-1 ligand-1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Solid tumours
Most Recent Events
- 28 Feb 2025 No recent reports of development identified for phase-I development in Solid-tumours(In volunteers, In adults) in United Kingdom (PO, Tablet)
- 03 May 2024 700327195: CTP push: KDM, DevT, HE updated for missing countries, KDM and HE updated for trial termination
- 26 Mar 2024 Incyte Corporation terminates a phase II trial in Solid tumours in Hungary, Bulgaria, South Korea, Taiwan, Romania, Ukraine (PO) (NCT04629339) (EudraCT2020-000157-27)